Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial
Cardiovascular Drugs and Therapy · 2025
DOI: 10.1007/s10557-024-07585-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Chisato Izumi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Heart Failure and Transplant, National Cerebral and Cardiovascular Center, 6-1 Kishibe Shimmachi, Suita-City, Osaka, 564-8565, Japan. i…. Hauptthemen laut MEDLINE: Anticoagulants, Bioprosthesis, Factor Xa Inhibitors, Heart Valve Prosthesis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Daiichi Sankyo Company.
Abstract (Originalsprache)
BACKGROUND AND PURPOSE: Anticoagulant therapy with vitamin K antagonists is recommended within 3 to 6 months after bioprosthetic valve replacement to prevent thromboembolic events. However, data regarding whether direct oral anticoagulants can be an alternative to warfarin in such patients are limited. The purpose of this study is to compare the efficacy and safety of edoxaban versus warfarin within 3 months after bioprosthetic valve replacement. METHODS: The ENBALV trial is an investigator-initiated, phase 3, randomized, open-label, multicenter study. It involves patients aged 18 to 85 years undergoing bioprosthetic valve replacement at the aortic and/or mitral position. They are randomized 1:1 to receive either edoxaban or warfarin. Administration of edoxaban or warfarin is to be continued for 12 weeks after surgery. The primary outcome is the occurrence rate of stroke or systemic embolism at 12 weeks after surgery. The net clinical outcome is a composite of stroke, systemic embolism, or major bleeding, which is included in the secondary outcomes. CONCLUSION: The ENBALV trial demonstrates the efficacy and safety of edoxaban compared with warfarin in patients early after bioprosthetic valve replacement, including patients with sinus rhythm, which will bring a significant benefit to patients in clinical practice. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT) 2051210209. 30 Mar 2022 https://jrct.niph.go.jp/latest-detail/jRCT2051210209 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Heart Failure and Transplant, National Cerebral and Cardiovascular Center, 6-1 Kishibe Shimmachi, Suita-City, Osaka, 564-8565, Japan. izumi-ch@ncvc.go.jp.
- Department of Heart Failure and Transplant, National Cerebral and Cardiovascular Center, 6-1 Kishibe Shimmachi, Suita-City, Osaka, 564-8565, Japan.
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan.
- Department of Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Cardiovascular Surgery, Hakujyuji Hospital, Fukuoka, Japan.
- Department of Cardiovascular Surgery, Hyogo Medical University, Nishinomiya, Japan.
ORCID-Profile: Chisato Izumi
Förderung
- Daiichi Sankyo Company
Zitieren
APA
Izumi, C., Amano, M., Fukushima, S., Yaku, H., Eishi, K., Sakaguchi, T., Minami, M., Yamamoto, H., Onda, K., & Omae, K. (2025). Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07585-x
Vancouver
Izumi C, Amano M, Fukushima S, Yaku H, Eishi K, Sakaguchi T, et al. Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07585-x
BibTeX
@article{Izumi2025,
author = {Izumi, Chisato and Amano, Masashi and Fukushima, Satsuki and Yaku, Hitoshi and Eishi, Kiyoyuki and Sakaguchi, Taichi and Minami, Manabu and Yamamoto, Haruko and Onda, Kaori and Omae, Katsuhiro},
title = {Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
doi = {10.1007/s10557-024-07585-x}
}
EUVIMED